Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17571385 | 0.83 | TSHR (0.43) | TSHRL3MBTL1MAPK1PTK2TDP1 | |
| SCHEMBL17559576 | 0.82 | HCAR3 (0.46) | TSHRL3MBTL1MAPK1PTK2TDP1 | |
| SCHEMBL17559726 | 0.81 | F10 (0.42) | TSHRTDP1NPC1NPSR1HTT | |
| SCHEMBL19435365 | 0.81 | F10 (0.42) | TSHRTDP1NPC1NPSR1HTT | |
| SCHEMBL21969950 | 0.79 | F10 (0.40) | TSHRL3MBTL1MAPK1NPC1NPSR1 | |
| SCHEMBL22679027 | 0.78 | F10 (0.36) | TSHRL3MBTL1MAPK1PTK2TDP1 | |
| SCHEMBL17559595 | 0.77 | HCRTR1 (0.52) | — | |
| SCHEMBL17559596 | 0.77 | HCRTR1 (0.52) | — | |
| SCHEMBL17559611 | 0.76 | TSHR (0.47) | TSHRL3MBTL1MAPK1PTK2TDP1 | |
| SCHEMBL19435313 | 0.76 | HCRTR1 (0.43) | TSHRMAPK1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024509-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | C4X DISCOVERY LIMITED (GB) | 2024-07-02 | — | — | US | disclosed |
| EP-3189043-B1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | C4X DISCOVERY LTD (GB) | 2020-11-18 | — | — | EP | disclosed |
| US-20200270247-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | C4X DISCOVERY LIMITED | 2020-08-27 | — | — | US | disclosed |
| US-10611760-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | C4X DISCOVERY LIMITED (GB) | 2020-04-07 | — | — | US | disclosed |
| US-20170291897-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | INDIVIOR INC. | 2017-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024509-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | HCRTR1, HCRTR2, NPY1R | TSHR 166/4885L3MBTL1 4730/4885MAPK1 705/4885 |
| US-20200270247-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | HCRTR1, HCRTR2, NPY1R | TSHR 166/4885L3MBTL1 4730/4885MAPK1 705/4885 |
| US-10611760-B2 | Therapeutic compounds as inhibitors of the orexin-1 receptor | HCRTR1, HCRTR2, NPY1R | TSHR 166/4885L3MBTL1 4730/4885MAPK1 705/4885 |
| US-20170291897-A1 | THERAPEUTIC COMPOUNDS AS INHIBITORS OF THE OREXIN-1 RECEPTOR | HCRTR1, HCRTR2, NPY1R | TSHR 166/4885L3MBTL1 4730/4885MAPK1 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.